We are live on ! Find out more
LGND icon

Ligand Pharmaceuticals
LGND

116 hedge funds and large institutions have $640M invested in Ligand Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 116 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

3% less call options, than puts

Call options by funds: $4.19M | Put options by funds: $4.33M

Holders
116
Holders Change
+116
Holders Change %
–
% of All Funds
3.79%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.16%
New
116
Increased
–
Reduced
–
Closed
–
Calls
$4.19M
Puts
$4.33M
Net Calls
-$140K
Net Calls Change
-$140K

Top Buyers

No buyers this quarter

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
BA
51
BlackRock Advisors
Delaware
$1.16M +$894K +49,730 New
AM
52
Anthion Management
New York
$1.15M +$888K +49,374 New
State Board of Administration of Florida Retirement System
53
State Board of Administration of Florida Retirement System
Florida
$1.03M +$792K +44,062 New
CC
54
Cornerstone Capital
California
$958K +$738K +41,061 New
PP
55
Paloma Partners
Connecticut
$936K +$721K +40,075 New
WMSA
56
Weiss Multi-Strategy Advisers
New York
$935K +$721K +40,075 New
TC
57
TFS Capital
Pennsylvania
$909K +$701K +38,959 New
Jane Street
58
Jane Street
New York
$908K +$700K +38,913 New
TA
59
Teachers Advisors
New York
$889K +$685K +38,081 New
PNC Financial Services Group
60
PNC Financial Services Group
Pennsylvania
$876K +$675K +37,542 New
DC
61
Deere & Company
Illinois
$841K +$649K +36,061 New
VRS
62
Virginia Retirement Systems
Virginia
$834K +$643K +35,747 New
JP Morgan Chase
63
JP Morgan Chase
New York
$761K +$586K +32,608 New
DCM
64
Driehaus Capital Management
Illinois
$743K +$572K +31,831 New
Connor, Clark & Lunn Investment Management (CC&L)
65
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$742K +$542K +30,136 New
Swiss National Bank
66
Swiss National Bank
Switzerland
$711K +$548K +30,457 New
PPA
67
Parametric Portfolio Associates
Washington
$702K +$541K +30,080 New
GC
68
Globeflex Capital
California
$685K +$529K +29,401 New
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
$674K +$519K +28,881 New
WPC
70
White Pine Capital
Minnesota
$639K +$492K +27,371 New
DLCIG
71
D.L. Carlson Investment Group
New Hampshire
$596K +$459K +25,528 New
ProShare Advisors
72
ProShare Advisors
Maryland
$568K +$438K +24,345 New
TAM
73
Tocqueville Asset Management
New York
$561K +$432K +24,045 New
VOYA Investment Management
74
VOYA Investment Management
Georgia
$543K +$419K +23,279 New
OAM
75
Oberweis Asset Management
Illinois
$524K +$404K +22,442 New
1 2
3
4 5

LGND Hedge Fund Activity: Q2 2013 in Review

116 of the 3,064 institutional investors tracked by Wall St. Rank reported a position in Ligand Pharmaceuticals (LGND) for Q2 2013, worth a combined $640M.

Buyers outnumbered sellers: 116 funds opened new LGND positions and 0 closed out — a net gain of 116 holders — while 0 added to existing stakes and 0 trimmed.

  • 116 institutional investors held Ligand Pharmaceuticals (LGND) as of Q2 2013, up from 0 in Q1 2013.
  • Funds reported $640M of Ligand Pharmaceuticals stock for Q2 2013.
  • 116 funds opened new Ligand Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +116 holders.

Based on aggregated 13F filings for Q2 2013.